| Literature DB >> 35744788 |
Jia Wu1, Zai-Qi Zhang2, Xu-Dong Zhou1, Qing-Ying Yao1, Zhu-Liang Chen1, Ling-Ling Chu1, Huang-He Yu1, Yu-Pei Yang1, Bin Li1, Wei Wang1.
Abstract
Two new A-ring contracted triterpenoids, madengaisu A and madengaisu B, and one undescribed ent-kaurane diterpenoid, madengaisu C, along with 20 known compounds were isolated from the roots of Potentilla freyniana Bornm. The structures were elucidated using extensive spectroscopic techniques, including 1D and 2D-NMR, HR-ESI-MS, ECD spectra, IR, and UV analysis. Moreover, all isolated constituents were evaluated for their anti-proliferative activity against RA-FLS cells and cytotoxic activities against the human cancer cell lines Hep-G2, HCT-116, BGC-823, and MCF-7. Ursolic acid and pomolic acid displayed moderate inhibitory activity in RA-FLS cells with IC50 values of 24.63 ± 1.96 and 25.12 ± 1.97 μM, respectively. Hyptadienic acid and 2α,3β-dihydroxyolean-12-en-28-oic acid 28-O-β-d-glucopyranoside exhibited good cytotoxicity against Hep-G2 cells with IC50 values of 25.16 ± 2.55 and 17.66 ± 1.82 μM, respectively. In addition, 2α,3β-dihydroxyolean-13(18)-en-28-oic acid and alphitolic acid were observed to inhibit HCT-116 cells (13.25 ± 1.65 and 21.62 ± 0.33 μM, respectively), while madengaisu B and 2α,3β-dihydroxyolean-13(18)-en-28-oic acid showed cytotoxic activities against BGC-823 cells with IC50 values of 24.76 ± 0.94 and 26.83 ± 2.52 μM, respectively, which demonstrated that triterpenes from P. freyniana may serve as therapeutic agents for RA and cancer treatment.Entities:
Keywords: A-ring contracted triterpenoids; Dong ethnomedicine; Potentilla freyniana Bornm.; cytotoxic activities; ent-kaurane diterpenoids
Mesh:
Substances:
Year: 2022 PMID: 35744788 PMCID: PMC9227482 DOI: 10.3390/molecules27123665
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Chemical structures of compounds 1–23.
The 1H and 13C-NMR data of 1 and 2 (600/150 MHz, CD3OD, δ in ppm, J in Hz).
| Position | 1 | 2 | ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 61.4 | 4.16, dd (14.5, 1.8) | 61.4 | 4.16, dd (14.5, 1.8) |
| 2 | 156.0 | - | 156.1 | - |
| 3 | 135.4 | 5.40, s | 135.5 | 5.39, s |
| 4 | 43.3 | - | 43.3 | - |
| 5 | 64.5 | 1.44, m | 64.4 | 1.41, m |
| 6 | 18.2 | 1.52, m | 18.2 | 1.49, m |
| 7 | 34.9 | a 1.56, m | 35.4 | a 1.58, m |
| 8 | 42.1 | - | 42.3 | - |
| 9 | 44.9 | 2.15, m | 44.8 | 2.09, m |
| 10 | 51.8 | - | 51.7 | - |
| 11 | 27.5 | b 2.19, m | 27.4 | b 2.18, m |
| 12 | 123.6 | 5.25, t (3.5) | 126.8 | 5.22, t (3.5) |
| 13 | 145.7 | - | 140.1 | - |
| 14 | 43.2 | - | 43.5 | - |
| 15 | 29.1 | b 1.83, dt (13.8, 4.3) | 29.5 | b 1.95, td (13.6, 4.5) |
| 16 | 24.0 | a 2.05, m | 25.3 | a 2.05, m b |
| 17 | 47.7 | - | (48.6) * | - |
| 18 | 43.0 | 2.85, dd (13.9, 4.6) | 54.5 | 2.20, m |
| 19 | 47.0 | a 1.72, m | 40.2 | 1.38.m |
| 20 | 31.6 | - | 40.4 | 0.97, overlapped |
| 21 | 35.1 | a 1.42, m | 31.7 | 1.51, m |
| 22 | 33.8 | b 1.77, m | 38.1 | 1.68, m |
| 23 | 30.3 | 1.04, s | 30.3 | 1.03, s |
| 24 | 21.8 | 0.96, s | 21.8 | 0.95, s |
| 25 | 19.3 | 1.16, s | 19.3 | 1.16, s |
| 26 | 19.2 | 0.87, s | 19.3 | 0.90, s |
| 27 | 26.8 | 1.20, s | 24.3 | 1.15, s |
| 28 | 181.9 | - | 181.7 | - |
| 29 | 33.6 | 0.91, s | 17.7 | 0.90, d (6.6) |
| 30 | 24.0 | 0.95, s | 21.6 | 0.96, d (4.8) |
a: α-oriented proton. b: β-oriented proton. * Overlapped with the solvent peak.
Figure 2(a) Key 1H-1H COSY and HMBC correlations of 1. (b) Selected ROESY correlations of 1.
Figure 3Experimental and calculated ECD spectra of 1.
Figure 4(a) Key 1H-1H COSY and HMBC correlations of 2. (b) Selected ROESY correlations of 2.
Figure 5Experimental and calculated ECD spectra of 2.
The 1H and 13C-NMR data of compound 22 (600/150 MHz, CD3OD, δ in ppm, J in Hz).
| Position | 22 | Position | 22 | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| 1 | 42.2 | 1.91, m | 15 | 46.2 | 1.67, overlapped |
| 2 | 20.4 | 1.92, m | 16 | 41.2 | 2.26, m |
| 3 | 39.3 | 2.13, overlapped | 17 | 69.9 | 4.09, d (1.7) |
| 4 | 44.8 | - | 18 | 29.6 | 1.19, s |
| 5 | 58.3 | 1.07, overlapped | 19 | 182.4 | - |
| 6 | 23.7 | 1.87, m | 20 | 16.3 | 0.99, s |
| 7 | 42.9 | 1.50, m | 1′ | 122.8 | - |
| 8 | 46.2 | - | 2′ | 113.5 | 7.54, d (2.0) |
| 9 | 56.8 | 1.07, overlapped | 3′ | 148.8 | - |
| 10 | 40.8 | - | 4′ | 152.9 | - |
| 11 | 19.8 | 1.69, overlapped | 5′ | 116.0 | 6.85, d (8.8) |
| 12 | 32.5 | 1.60, m | 6′ | 125.0 | 7.55, dd (2.0 8.7) |
| 13 | 40.2 | 2.16, m | 7′ | 168.4 | - |
| 14 | 38.3 | 1.95, m | -OCH3 | 56.4 | 3.90, s |
Figure 6Key 2D-NMR correlations of compound 22.
Figure 7Experimental and calculated ECD spectra of compound 22.
Figure 8Plausible biosynthetic pathway for 2–4 and 6–12.
Cytotoxic effects of tested compounds on RA-FLS and human cancer cell lines.
| Compound | IC50 (μM) a | ||||
|---|---|---|---|---|---|
| Anti-RA-FLS Activity | Anti-Tumor Activity | ||||
| RA-FLS | Hep-G2 | HCT-116 | BGC-823 | MCF-7 | |
|
| >30 b | >30 | >30 | 24.76 ± 0.94 | >30 |
|
| >30 | 25.16 ± 2.55 | >30 | >30 | >30 |
|
| 24.63 ± 1.96 | >30 | >30 | >30 | >30 |
|
| 25.12 ± 1.97 | >30 | >30 | >30 | >30 |
|
| >30 | >30 | 13.25 ± 1.65 | 26.83 ± 2.52 | >30 |
|
| >30 | 17.66 ± 1.82 | >30 | >30 | >30 |
|
| >30 | >30 | 21.62 ± 0.33 | >30 | >30 |
| Methotrexate c | 5.09 ± 0.60 | - | - | - | - |
| Taxol (nM) c | - | 13.82 ± 0.78 | 15.79 ± 0.91 | 9.12 ± 1.23 | - |
a IC50, the half maximal inhibitory concentration. Values represent the mean ± SD of three independent experiments. b Compounds exhibiting IC50 values > 30 μM were considered to be inactive. c Methotrexate as positive control for anti-RA-FLS activity test and taxol for anti-tumor activity test.